Form D · Biotechnology
Thrive Bioscience, Inc.
Wakefield, MA · CIK 0001642601
Offering snapshot reported Aug 28, 2017 · SEC filing
- Reported sold
- $1.8M Offering amount: $2.5M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- May 19, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 28, 2017 | Initial | $1,801,885 | No comparison | 21 | SEC filing |
| Mar 7, 2017 | Initial | $7,150,000 | No comparison | 36 | SEC filing |
| Dec 11, 2015 | Initial | $2,175,000 | No comparison | 20 | SEC filing |
| May 15, 2015 | Initial | $3,257,589 | No comparison | 24 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-293560
Source: Form D, filed Aug 28, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alan Philippe Blanchard | Director, Executive |
| Guy Broadbent | Director |
| Thomas Forest Farb | Director, Executive |
| Michael Finney | Director |
| Gary Paul Magnant | Director, Executive |
| Brock Reeve | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11 Audubon Road
Wakefield, MA, 01880
Wakefield, MA, 01880